Incyte Announces 52-Week Data From the Phase 3 TRuE-V Progra

Use of ruxolitinib cream (Opzelura) resulted in further improvement in facial and total body repigmentation at Week 52 Results will be featured as an oral presentation in a late-breaking abstract session

Related Keywords

Delaware , United States , Boston , Massachusetts , Ohio , American , Erica Cech , David Rosmarin , Christine Chiou , Jenifer Antonacci , Jim Lee , Group Vice , Drug Administration , Department Of Dermatology At Tufts Medical Center , Exchange Commission , American Academy Of Dermatology , European Medicines Agency , Incyte Corporation , Breaking Research , Clinical Trials , Annual Meeting , Vitiligo Area Scoring , Vitiligo Area Scoring Index , Vitiligo Noticeability Scale , Group Vice President , Inflammation Autoimmunity , Vice Chair , Tufts Medical , Drug User Fee Act , Ruxolitinib Cream , European Marketing Authorization Application , Mississippi River , Incyte , Nnounces , Eek , Data , Rom , Hase , True , Program , Valuating , Ruxolitinib , Cream , Opzelura , Patients , Ith , Vitiligo ,